AccScience Publishing / TD / Online First / DOI: 10.36922/td.3275
CASE REPORT

E-cadherin-positive and strong P53-positive acute erythroleukemia in an elderly man: A case report

Yasuhiro Kazuma1 Yutaka Shimazu1,2 Keisuke Shindo1 Naoyuki Anzai1 Miyako Kobayashi1 Satoko Mibayashi3 Shinsaku Imashuku1,4*
Show Less
1 Department of Hematology, Uji-Tokushukai Medical Center, Uji, Kyoto, Japan
2 Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
3 Department of Diagnostic Pathology, Uji-Tokushukai Medical Center, Uji, Kyoto, Japan
4 Department of Laboratory Medicine, Uji-Tokushukai Medical Center, Uji, Kyoto, Japan
Tumor Discovery 2024, 3(3), 3275 https://doi.org/10.36922/td.3275
Submitted: 26 March 2024 | Accepted: 12 June 2024 | Published: 4 September 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Acute erythroleukemia (FAB M6), a rare form of acute myeloid leukemia, consists of two subtypes: M6a-erythroid/myeloid leukemia and M6b-pure erythroid leukemia (PEL). The diagnosis of PEL is often difficult due to the negativity of classical erythroid cell markers. Recently, an epithelial calcium-dependent cell adhesion protein (E-cadherin) has been identified as a marker of immature erythroid precursors. Here, we report an elderly case of PEL in which E-cadherin positivity and strong P53 positivity were the key clues for diagnosis. The patient was treated with a daunomycin/Ara-C regimen followed by a venetoclax/azacitidine regimen but responded to neither treatment.

Keywords
Acute erythroleukemia
Pure erythroid leukemia
E-cadherin
P53
Funding
None.
Conflict of interest
The authors declare no conflicts of interest.
References
  1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405. doi: 10.1182/blood-2016-03-643544

 

  1. Weinberg OK, Arber DA. Erythroleukemia: An update. Curr Oncol Rep. 2021;23(6):69. doi: 10.1007/s11912-021-01060-8

 

  1. Reichard KK, Tefferi A, Abdelmagid M, et al. Pure (acute) erythroid leukemia: Morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases. Blood Cancer J. 2022;12(11):147. doi: 10.1038/s41408-022-00746-x

 

  1. Ohgami RS, Chisholm KM, Ma L, Arber DA. E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms. Am J Clin Pathol. 2014;141(5):656-664. doi: 10.1309/AJCP8M4QQTAZPGRP

 

  1. Tamura A, Uemura S, Saito A, et al. Congenital immature pure erythroid leukemia with E-cadherin expression. Int J Hematol. 2017;106(5):711-717. doi: 10.1007/s12185-017-2248-7

 

  1. Caldwell I, Ruskova A, Royle G, Liang J, Bain BJ. Pure erythroid leukemia: The value of E-cadherin in making the diagnosis. Am J Hematol. 2019;94(6):726-727. doi: 10.1002/ajh.25437

 

  1. Jakobiec FA, Wolkow N, Zakka FR, Rubin PAD. Myeloid sarcoma with megakaryoblastic differentiation arising in the conjunctiva. Ocul Oncol Pathol. 2019;5(1):28-35. doi: 10.1159/000488057

 

  1. Iacobucci I, Wen J, Meggendorfer M, et al. Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet. 2019;51:694-704. doi: 10.1038/s41588-019-0375-1

 

  1. Strouboulis J. Erythroleukemia: All roads lead to GATA1? Blood. 2020;136(6):648-649. doi: 10.1182/blood.2020006107

 

  1. Kallakury BV, Figge J, Ross JS, Fisher HA, Figge HL, Jennings TA. Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol. 1994;25(1):92-97. doi: 10.1016/0046-8177(94)90177-5

 

  1. Limani R, Lež C, Krušlin B. Exploring the relationship between E-cadherin and β-catenin cell adhesion proteins and periacinar retraction clefting in prostatic adenocarcinoma. Diagnostics (Basel). 2024;14(5):511. doi: 10.3390/diagnostics14050511

 

  1. Domingo-Claros A, Larriba I, Rozman M, et al. Acute erythroid neoplastic proliferations. A biological study based on 62 patients. Haematologica. 2002;87(2):148-153.

 

  1. Takeda J. Molecular pathogenesis and therapeutic targets in acute erythroid leukemia. Rinsho Ketsueki. 2022;63(2):121-133. [Article in Japanese] doi: 10.11406/rinketsu.63.121
Share
Back to top
Tumor Discovery, Electronic ISSN: 2810-9775 Print ISSN: 3060-8597, Published by AccScience Publishing